United States Patent 8,003,673 (Daptomycin + Lactated Ringer’s) Scope, Claims, and US Patent Landscape
US Patent 8,003,673 centers on method-of-treatment and device-associated biofilm control using daptomycin formulated in lactated Ringer’s solution and, in catheter settings, daptomycin with calcium (including catheter-lock exposure regimes). The claim set is tight around (i) daptomycin in specific solution matrices (lactated Ringer’s; physiological calcium), (ii) exposure timing (short-contact minimums and an 18-hour lock window), (iii) operating dose/concentration ranges (notably ≥1 mg/mL, ≥5 mg/mL, and ~5 mg/mL), and (iv) delivery concepts (direct application to the biofilm and catheter lock therapy). These constraints shape infringement risk for any generic-like or reformulated approach that departs from the matrix, concentration, or exposure schedule.
What does US Patent 8,003,673 claim cover for daptomycin biofilm treatment?
Core claim architecture: the patent claims (A) treating a biofilm by applying a daptomycin solution in lactated Ringer’s and (B) treating or preventing catheter biofilms by exposing device surfaces (notably catheter lumens) to daptomycin with calcium, including catheter lock therapy concepts, exposure duration, and a kit.
Independent claim scope (implied by your claim set numbering)
Claim 1 (biofilm treatment, lactated Ringer’s + daptomycin)
- “A method for treating a biofilm”
- providing a solution of daptomycin in lactated Ringer’s solution
- applying/using the solution to the biofilm (explicitly tightened in dependent claims)
Practical scope levers
- Biofilm is broad: not limited to a species, tissue type, or catheter vs non-catheter context in Claim 1 alone.
- The formulation matrix is a key limiting feature: lactated Ringer’s.
Claim 10 (device surface treatment, daptomycin + calcium)
- “A method of treating or preventing a biofilm”
- “exposing a surface of a device to a solution comprising daptomycin and calcium”
- device surface scope is defined by dependent claims (catheter lumen and catheter lock therapy), but Claim 10 itself is device-agnostic.
Practical scope levers
- This claim expands away from lactated Ringer’s alone by adding calcium as a required co-ingredient.
- It can capture approaches that use a calcium-containing buffer even if not expressly lactated Ringer’s, depending on claim construction of “calcium” and “comprising.”
Dependent claim scope tightening (timing, dosing, concentration, delivery)
Your dependent claims add multiple layers that narrow infringement if a competitor changes any one element.
Contact time
- Claim 2: treatment at least 30 minutes
- Claim 5: about 30 minutes
- Claim 14: catheter lock therapy exposure for about 18 hours
These create multiple infringement “entry points”. A device lock regimen that hits 18 hours is especially positioned against Claim 14, while shorter direct application may still land under Claim 2 or Claim 5.
Application strategy
- Claim 3 and 4: applying “until the biofilm is reduced” and “reduced and does not reoccur”
- The “does not reoccur” limitation increases enforceability difficulty because it introduces an outcome/recurrence concept that may depend on time horizon and testing conditions.
Frequency
- Claim 6: “twice per day”
- Claim 7: “at least four times per day”
Frequency constraints may matter for practices that use a single lock or variable instillations.
Daptomycin concentration
- Claim 8: concentration ≥ 1 mg/mL
- Claim 9: concentration ≥ 5 mg/mL
- Claim 13 and 17: “about 5 mg/mL” with physiological calcium and exposure ≥ about 30 minutes
These are strong numeric anchors. A competitor using materially lower concentration than 1 mg/mL or using a distinctly different target concentration may fall outside the literal concentration limits.
Catheter lock specifics
- Claim 11: further comprising performing a heparin flush (in luminal catheter use)
- Claims 12, 18, 19:
- surface forms a portion of a catheter (Claim 11)
- inner luminal surface exposed by catheter lock therapy (Claim 12)
- catheter is a central venous catheter (Claim 18)
- method of treating catheter biofilm with ~5 mg/mL daptomycin in lactated Ringer’s (Claim 19)
The catheter-specific claims braid together (i) the physical setting (inner luminal surface), (ii) the delivery mode (catheter lock), and (iii) the matrix (lactated Ringer’s) plus concentration.
Kit
- Claim 20: a kit comprising lactated Ringer’s solution having daptomycin “in an amount sufficient to treat the biofilm.”
A kit claim can expand exposure to manufacturers supplying premixed solutions even if the dosing regimen is executed by providers.
Claim-by-claim infringement risk map: what elements must be met?
Below is a practical “all-elements” checklist based on your claim set.
Table: Limiting features by claim
| Claim |
Method setting |
Required solution components |
Concentration floor |
Exposure timing |
Delivery/structure limits |
Extra outcome limits |
| 1 |
Biofilm (broad) |
Daptomycin + lactated Ringer’s |
None stated here |
None stated here (later claims) |
Treat biofilm |
None |
| 2 |
Biofilm |
Same as Claim 1 |
None stated |
≥ 30 min |
N/A |
None |
| 3 |
Biofilm |
Same as Claim 1 |
None |
N/A |
Apply until reduced |
None |
| 4 |
Biofilm |
Same as Claim 1 |
None |
N/A |
Apply until reduced |
“does not reoccur” |
| 5 |
Biofilm |
Same as Claim 1 |
None |
“about 30 min” |
N/A |
None |
| 6 |
Biofilm |
Same as Claim 1 |
None |
N/A |
Twice/day |
None |
| 7 |
Biofilm |
Same as Claim 1 |
None |
N/A |
≥4x/day |
None |
| 8 |
Biofilm |
Same as Claim 1 |
≥1 mg/mL |
N/A |
N/A |
None |
| 9 |
Biofilm |
Same as Claim 1 |
≥5 mg/mL |
N/A |
N/A |
None |
| 10 |
Device biofilm |
Daptomycin + calcium |
None stated |
None stated |
Expose device surface |
None |
| 11 |
Catheter |
Daptomycin + calcium |
None |
None stated |
Catheter surface; includes heparin flush |
None |
| 12 |
Catheter lumen |
Daptomycin + calcium |
None |
Exposed by catheter lock therapy |
Inner luminal surface |
None |
| 13 |
Catheter |
Daptomycin (~5 mg/mL) + physiologic calcium |
~5 mg/mL |
None stated |
— |
None |
| 14 |
Catheter lock |
Daptomycin + calcium |
None stated |
~18 hours |
Catheter lock therapy |
None |
| 15 |
Catheter/Device |
Daptomycin + lactated Ringer’s |
None stated |
None stated |
Expose surface |
None |
| 16 |
Catheter |
Daptomycin + calcium |
None stated |
None stated |
Performs heparin flush |
None |
| 17 |
Catheter lumen |
~5 mg/mL + lactated Ringer’s; or at least includes these features per claim text |
~5 mg/mL |
≥ about 30 min |
Exposed to solution by catheter lock therapy |
None |
| 18 |
Central venous catheter |
Daptomycin + calcium |
None stated |
None stated |
Central venous catheter |
None |
| 19 |
Catheter (lumen) |
~5 mg/mL daptomycin in lactated Ringer’s |
~5 mg/mL |
None stated |
Inner luminal surface; catheter biofilm |
None |
| 20 |
Kit |
Lactated Ringer’s + daptomycin |
“amount sufficient” |
N/A |
Kit |
None |
Key takeaway for infringement analysis: A design-around can target any one of: (i) matrix (avoid lactated Ringer’s), (ii) calcium co-formulation, (iii) daptomycin concentration thresholds (particularly 1 mg/mL and 5 mg/mL), (iv) exposure duration regimes (30 minutes minimum; 18-hour lock), (v) catheter-lumen lock architecture, or (vi) supplying a premixed kit.
How broad is US Patent 8,003,673 across biofilm types, devices, and delivery routes?
Biofilm coverage
- Claim 1 is biofilm-agnostic (no organism specificity in the claim text you provided).
- That increases the breadth to any biofilm context that can be characterized as “a biofilm” under claim construction.
Device surface coverage
- Claim 10 is device-agnostic at the independent level, but dependent claims anchor to catheters, particularly central venous catheters, and inner luminal surfaces.
Delivery routes
- Claim 1 supports “providing a solution” and, via dependent claims, “applying” to reduce biofilm.
- Claims 10-19 cover catheter lock therapy. The lock concept is a distinct delivery regime that many real-world protocols follow, increasing practical relevance.
Solution composition limitations
- There are two compositional “anchors”:
- Lactated Ringer’s (Claim 1 and lactated Ringer’s-related dependent claims such as 15 and 19).
- Daptomycin + calcium (Claim 10 and catheter-lock dependent claims including 13 and 14).
This dual structure can be interpreted as capturing both:
- daptomycin instilled in lactated Ringer’s, and
- daptomycin instilled in calcium-containing solutions (which may or may not be lactated Ringer’s).
What formulations are protected: lactated Ringer’s, calcium, and ~5 mg/mL daptomycin?
Protected concentration “tripwires”
Your claim set repeatedly uses numeric concentration thresholds:
- ≥ 1 mg/mL (Claim 8)
- ≥ 5 mg/mL (Claim 9)
- ~5 mg/mL (Claims 13, 17, 19)
These create three distinct infringement bands:
- If a competitor uses 1–4.99 mg/mL, Claim 8 is still at risk.
- If they use ≥5 mg/mL, both Claims 9 and the “about 5 mg/mL” dependent claims become relevant.
- “About 5 mg/mL” can capture slight deviations depending on claim construction.
Calcium requirement
- Claim 10 requires “daptomycin and calcium.”
- Claim 13 specifies “physiological concentration of calcium.”
- Claim 14 ties exposure duration to catheter lock therapy.
A design-around that eliminates calcium or uses a solution where calcium is absent at the physiological level would aim to avoid Claim 10/13/14, but if the competitor also uses lactated Ringer’s, the lactated Ringer’s-related claims could still be implicated.
Lactated Ringer’s requirement
- Claim 1 and lactated Ringer’s dependent claims require “lactated Ringer’s solution.”
- Claim 19 explicitly locks to “about 5 mg/mL daptomycin in lactated Ringer’s.”
When does US Patent 8,003,673 lose exclusivity?
No filing, priority, issuance, or expiration schedule is provided in the prompt. Without those specific bibliographic facts for US 8,003,673 (filing date, application number, priority claims, and whether any adjustments apply), an exclusivity or expiration timeline cannot be produced accurately.
What generic entry risks exist if competitors use daptomycin lock solutions?
This is a method-of-use and kit risk, not a composition-permission risk.
Risk scenario 1: “Same protocol, different manufacturer”
If a competitor’s catheter-lock protocol uses:
- daptomycin in lactated Ringer’s,
- concentration at or above the cited thresholds,
- and exposure times in the claimed windows,
then they can directly infringe method claims regardless of whether they source daptomycin from the same supplier.
Risk scenario 2: “Same daptomycin, different matrix”
If they switch away from lactated Ringer’s but keep calcium and concentration/time regimes, they may still face Claim 10/13/14 exposure. If they avoid both lactated Ringer’s and physiological calcium, the risk can be reduced against the independent claim.
Risk scenario 3: “Lower concentration, shorter dwell time”
- Reducing below 1 mg/mL aims to exit Claim 8.
- Using less than 30 minutes aims to exit Claims 2 and 5 and the “at least about 30 minutes” catheter-lumen dependent claim.
- Avoiding ~18-hour catheter lock aims to reduce risk under Claim 14.
Risk scenario 4: “Outcome-based ‘no reoccurrence’”
Claim 4 includes “does not reoccur.” Even if competitors achieve reduction, disputes can center on:
- measurement endpoints,
- follow-up duration,
- and whether “reoccur” is established as claimed.
How does this patent compare with typical daptomycin antimicrobial lock approaches?
US 8,003,673 is structured around a narrow set of operational parameters that commonly vary in practice:
- solution matrix,
- presence of calcium,
- concentration of daptomycin,
- dwell time,
- frequency.
That means the patent estate risk profile can be higher for standard catheter-lock workflows that land near the cited values (notably ~5 mg/mL and ~18 hours). Approaches that move the protocol outside those specific operating points may reduce literal risk but can still be challenged under doctrine-of-equivalents theories, depending on claim construction and prosecution history.
What litigation and PTAB events affect US 8,003,673?
No litigation, PTAB, reexamination, or settlement status is included in the prompt. A landscape of challenges and outcomes cannot be produced without those docket-level facts.
Orange Book status for US 8,003,673 and FDA regulatory context
The prompt does not provide:
- the drug application (NDA/ANDA/BLA),
- whether daptomycin is listed for the specific catheter-lock indication,
- or the Orange Book listing details tied to this patent.
A correct Orange Book status analysis cannot be generated from the provided information.
Patent estate: what related claims and continuations typically surround this kind of method?
You supplied only the claims text for US 8,003,673, not its specification disclosures, priority document family, or continuation/related patent IDs.
A robust “estate map” across:
- continuations,
- divisionals,
- continuation-in-part variants,
- and corresponding international filings
cannot be completed without patent bibliographic links.
Key Takeaways
- US 8,003,673 claims daptomycin-based biofilm treatment using lactated Ringer’s and, for device contexts, daptomycin with calcium, with catheter-lock methods as the central practical use case.
- The most actionable infringement levers are (i) lactated Ringer’s vs other matrices, (ii) calcium requirement, (iii) daptomycin concentration thresholds (≥1 mg/mL; ≥5 mg/mL; ~5 mg/mL), and (iv) exposure times (≥30 minutes; ~18-hour catheter lock).
- The kit claim creates supply-chain exposure for premixed lactated Ringer’s + daptomycin solutions “sufficient to treat the biofilm.”
- Exclusivity timing, Orange Book implications, and litigation/validity posture cannot be determined from the provided prompt.
FAQs
1) Does US 8,003,673 require lactated Ringer’s or only calcium?
Claim 1 is anchored to daptomycin in lactated Ringer’s. Claim 10 is anchored to daptomycin and calcium, without expressly requiring lactated Ringer’s at the independent level.
2) What daptomycin concentrations are explicitly called out?
Your claim set includes ≥1 mg/mL, ≥5 mg/mL, and several dependent claims using about 5 mg/mL.
3) What dwell times are most important for catheter lock infringement risk?
Your claims include at least 30 minutes for biofilm treatment and an about 18 hours exposure for catheter lock therapy.
4) Can a “heparin flush + catheter lock” protocol avoid the patent?
Any protocol that performs catheter lock therapy using daptomycin + calcium on an inner luminal catheter surface, in the claimed concentration and exposure regimes, remains within the claim set as provided, including the heparin flush limitations in the relevant dependent claims.
5) Is this patent a composition patent or a method/kit patent?
Based on the claims you provided, it is a method-of-use patent with a kit claim tied to lactated Ringer’s with daptomycin.
References
- US Patent 8,003,673 (claims provided in prompt).
